Compare Travere Therapeutics Inc. Common Stock (TVTX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs State Street PDR S&P Retail ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while State Street PDR S&P Retail ETF trades at $84.83 (market cap $374.32M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 13× State Street PDR S&P Retail ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| TVTX | XRT | |
|---|---|---|
Market Cap | $4.88B | $374.32M |
Volume | 1,668,577 | 3,523,512 |
Sector | Health | Broad Market / Factor |
52-Week High | $67.52 | $92.35 |
52-Week Low | $26.79 | $77.28 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XRT (SPDR S&P Retail ETF) trades at $84.33, showing minimal daily movement with a 0.21% gain. Technical indicators present a mixed picture with bearish moving averages but neutral overall signals. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with recent retail sales showing volatility. XRT has underperformed the broader market year-to-date, reflecting sector-specific challenges in the retail landscape.
The retail sector outlook remains cautious amid macroeconomic pressures, though potential trade resolution benefits and holiday sales projections offer some optimism. Key risks include consumer spending sensitivity to economic conditions and competitive pressures. Analyst sentiment leans neutral with expectations of continued relative underperformance versus broader market indices into 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
